



OPEN

Author Correction: mTORC1 Maintains the Tumorigenicity of SSEA-4⁺ High-Grade Osteosarcoma

Wu Zhang, Meng-Lei Ding, Jia-Nian Zhang, Jian-Ru Qiu, Yu-Hui Shen, Xiao-Yi Ding, Lian-Fu Deng, Wei-Bin Zhang & Jiang Zhu

Correction to: *Scientific Reports* <https://doi.org/10.1038/srep09604>, published online 08 April 2015

This Article contains an error in Figure 6, where the incorrect image was used for Figure 6c. The correct Figure 6 and its accompanying legend appear below.

Published online: 27 October 2021




Figure 6. Terminal differentiation induction by mTOR-inactivation decreases SSEA-4⁺ TICs in vivo. **(a)** SSEA-4⁺ cells ($1-50 \times 10^5$) from the different resources as indicated were subcutaneously inoculated into NOD/SCID mice. The oral administration of PBS (filled box) or 5 mg/kg RAD001 (filled circle) commenced 2 days later. Tumor volumes are shown as the means \pm SDs, $n = 3-5$. **(b, c)** Representative images of whole-body **(b)** or lung metastasis **(c)** bioluminescence 4 weeks following subcutaneous **(b)** or tail vein injection **(c)** of 1×10^5 PBS- or RAD001-treated SSEA-4⁺ Well5 cells (as in **(a)**) into NOD/SCID mice. **(d)** Two representative tissue samples retrieved from the PBS-treated and RAD001-treated groups, respectively. **(e)** Immunohistochemical staining of p-S6, SSEA-4, or OCN in xenografts retrieved from the PBS- or RAD001-treated group, as in **(a, b)**. Scale bars represent 100 μ m. HE: hematoxylin–eosin. **(f)** Secondary tumorigenic xenograft formation of tumor tissue or cells after post-PBS or -RAD001 treatment, as in **(a, b)** (upper panel). Secondary tumorigenic xenografting rates (n/n) are summarized in the bottom table ($P < 0.01$).



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021